Literature DB >> 2906920

Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).

A Wiecek1, F Kokot, W Grzeszczak.   

Abstract

It is well known that some antibiotics are particularly nephrotoxic. In the present study we investigated kidney function and AAP excretion (as an index of nephrotoxicity) in patients with urinary tract infection treated with CAZ or CTX plus TOB. The main cause of infection was E. coli in both treated groups. After 10 days of treatment similar beneficial effects were stated in both groups. At the end of treatment urinary AAP excretion in both groups was higher than before treatment. Despite a significant increase in urinary AAP in only one patient of each group, the serum creatinine level rose by more than 45 mumol/l. Monitoring of urinary AAP may be useful in early detection of nephrotoxicity caused by antibiotics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906920     DOI: 10.1007/BF02550604

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  [Clinical evaluation of ceftazidime and the combined administration of cefotaxime and tobramycin in the treatment of urinary tract infections. Prospective and randomized studies].

Authors:  A Wiecek; F Kokot; H Andrzejowska; W Grzeszczak
Journal:  Pol Tyg Lek       Date:  1986-09-29

2.  Enzymuria: a parameter for the assessment of potential nephrotoxicity of cephalosporins.

Authors:  A W Mondorf; J E Scherberich; G Heinert; W Schoeppe
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

3.  Is tubular function impaired during treatment with gentamicin or tobramycin?

Authors:  A Stålberg; S Wählin; C Henning; J Sellers; A Hamfelt
Journal:  J Antimicrob Chemother       Date:  1981-04       Impact factor: 5.790

4.  Gentamicin and tobramycin in patients with various infections--nephrotoxicity.

Authors:  G Kahlmeter; T Hallberg; C Kamme
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

5.  Ceftazidime and renal function.

Authors:  K Alestig; B Trollfors; R Andersson; L Olaison; M Suurküla; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

6.  Ceftazidime nephrotoxicity in rats.

Authors:  F C Luft; D W Visscher; D M Nierste; D K Blase; N A Walker; G R Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.

Authors:  U Diener; E Knoll; B Langer; H Rautenstrauch; D Ratge; H Wisser
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

8.  Study of alanine aminopeptidase excretion as a test of gentamicin nephrotoxicity.

Authors:  P G Davey; A M Geddes; D M Cowley
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

9.  Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin.

Authors:  P C Frimodt-Møller; P O Madsen
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

10.  Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin.

Authors:  J M Gatell; J G SanMiguel; V Araujo; L Zamora; J Maña; M Ferrer; M Bonet; M Bohe; M T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.